Trastuzumab Emtansine Extends Overall Survival for Metastatic Breast Cancer Patients, Study Shows

According to a recent study that treatment with trastuzumab emtansine extends progression-free and overall survival with no serious safety concerns in patients with metastatic HER-2 positive breast cancer. The Eastern Cooperative Oncology Group-Performance Status (ECOG-PS), thrombocytopenia, and cancer antigen 15-3 are all correlated with survival.

Photo: Breast Cancer Survival | InStyleHealth
The observational, single-center, retrospective research analyzed clinical data from 78 patients treated with trastuzumab emtansine for metastatic breast cancer from May 2016 through May 2019 at Kartal Dr. Lutfi Kirdar Education and Research Hospital in Istanbul, Turkey.

Researchers analyzed the following factors in relation to survival: cancer antigen 15-3 sensitivity, ECOG-PS, presence or absence of visceral metastases, presence of absence of cranial metastases, and treatment-related thrombocytopenia.

Average progression-free and overall survival among patients 7.8 and 21.1 months, correspondingly. With the 78 patients, 20 had an objective tumor response.

The trastuzumab emtansine was tolerable with a manageable safety profile, which was consistent with previous clinical studies. Prevalent adverse events were anemia, thrombocytopenia, fatigue, and increased levels of alkaline phosphatase.

For patients with ECOG-PS=2 revealed a worse progression-free and overall survival than those with ECOG-PS<2. For patients with cancer antigen 15-3 – sensitive breast cancer also had worse progression-free and overall survival.

Moreover, treatment-related thrombocytopenia was a significant prognostic factor for survival. For patients with this condition had 12 months progression-free survival, while those patients without this condition had only 4.1 months progression-free survival. Similarly, overall survival was much longer in patients with vs without thrombocytopenia (29.5 vs 11.8 months).

Researchers said that Ado-trastuzumab emtansine is an antibody-drug conjugate that combines the cytotoxic activity of emtansine with human epidermal growth factor receptor 2-targeted antitumor features of trastuzumab.

For complete details of the clinical research, click here.


Source: J Oncol Pharm Pract 2021;27:547-554

If you have any suggestions, please let us know.

Post a Comment (0)
Previous Post Next Post